FDA Panel Supports Continued Testing of Pain Drugs
WASHINGTON (AP) - A panel of arthritis experts has recommended that the federal government allow continued testing of an experimental class of pain drugs for arthritis, despite links to bone decay and joint failure.
The Food and Drug Administration's 21-member panel of arthritis experts voted unanimously that research on the nerve-blocking drugs should continue, with certain safety precautions to protect patients. Reports of joint failure led the agency to halt studies of the drugs in 2010.
Pfizer, Johnson & Johnson and Regeneron Pharmaceuticals have asked the FDA to lift the moratorium on testing of their drugs.
"There's clearly a worrisome safety signal, but in spite of that I think there's an unmet need in certain patient populations," said panelist Dr. Sherine Gabriel, of the Mayo Medical School of Rochester of Minnesota.
- FDA Review Favors First Drug for HIV Prevention
- FDA Approves "Plan B" for OTC Sale to Women Ages 15 and Up
- FDA Cracks Down on Illegal Diabetes Remedies
- Support for Legalizing Marijuana at All-Time High
- New Drug Suppliers to Ease Two Cancer Drug Shortages
- Your Health: New Technology For Managing Chronic Pain
- Your Health: Treating Sacroiliac Joint Pain
- The Dangers of a Drug Named "Molly "
- Your Health: Painting Up Support For Alzheimer's Care
- Weight Loss Drug Belviq Gets Overdue US Launch